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Introduction
Th is past year’s contributions from the ﬁ eld of Neuro-
science to Critical Care have been varied, covering an 
array of topics and diseases. Th ese include stroke, 
subarachnoid hemorrhage, hypothermia, meningitis, 
peripheral nervous system diseases, and delirium, which 
captured the lion’s share. We review these articles, 
discuss their scientiﬁ c contribution to the ﬁ eld, and their 
clinical relevance below.
Delirium
Delirium is a common condition in the ICU, though 
likely more encountered in general ICU than neuro-
intensive care units. Among other things, it is associated 
with increased length of stay and mortality [1,2]. Because 
of its high prevalence and morbid consequences, delirium 
is an important topic in critical care research. In 2011, 
ﬁ ve articles addressing issues including pathophysiology, 
diagnosis and treatment of delirium were published in 
Critical Care.
McGrane and colleagues [3] sought to investigate a 
possible relationship between serum procalcitonin, 
C-reactive protein and delirium. Procalcitonin and 
C-reactive protein are inﬂ ammatory biomarkers that 
have been linked to many acute neurological conditions, 
like stroke, and other critical illnesses [4]. Th is pros-
pective cohort study was part of a double-blind, random-
ized controlled trial comparing dexmedetomidine and 
lorazepam for sedation of mechanically ventilated 
patients (Maximizing Eﬃ  cacy of Target Sedation and 
Reducing Neurological Dysfunction or MENDS) [5]. 
Data were analyzed for 87 (of 103) patients enrolled in 
MENDS. Higher levels of procalcitonin, but not C-
reactive protein, were associated with fewer delirium/
coma free days (odds ratio (OR) 0.5, 95% conﬁ dence 
interval (CI) 0.3 to 1.0; P = 0.04), but neither biomarker 
showed a relationship with 28-day survival. Some of 
these results were contradicted by another study led by 
Van den Boogaard and colleagues [6], which was a pros-
pective observational single center study of 100 critically 
ill patients (50 with and 50 without delirium). Th ese 
patients were further divided into two groups, ‘inﬂ amed’ 
and ‘non-inﬂ amed’ based on the presence of at least two 
systemic inﬂ ammatory response syndrome (SIRS) criteria 
and a positive culture. Th e reason for this dichotomy is 
the suspected diﬀ erence in levels of inﬂ ammatory 
mediators between the groups. Multivariate regression 
analysis showed that IL-8 was independently associated 
with delirium in ‘inﬂ amed’ patients (OR 9, 95% CI 1.8 to 
44; P ≤ 0.05), and similarly IL-10 (OR 2.6, 95% CI 1.1 to 
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reported.
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5.9; P ≤ 0.05) and the amyloid beta protein Aβ1-42/40 (OR 
0.03, 95% CI 0.002 to 0.50; P  ≤  0.05) in ‘non-inﬂ amed’ 
patients. Procalcitonin was an important biomarker that 
predicted delirium, although this variable did not make it 
through the multivariate analysis. Based on these results, 
the authors speculate that the pathophysiology of 
delirium in diﬀ erent patient populations could vary, and 
thus potential therapy might need to be more targeted. 
Nonetheless, the recent studies prove that, to date, the 
optimal biomarker that could predict the occurrence of 
delirium remains elusive.
In another prospective observational study investigat-
ing the relationship between imbalance in cerebral 
oxygen supply/demand ratio and occurrence of delirium, 
Schoen and colleagues [7] used near infrared spectro-
scopy to measure pre- and intraoperative cerebral oxygen 
saturation (ScO2) in 231 patients undergoing on-pump 
cardiac surgery looking for a relationship between these 
measurements and development of post-operative 
delirium. In an earlier study, preoperative ScO2 was 
associated with postoperative morbidity and mortality in 
a similar cohort of patients [8]. Th e current investigation 
found that older age, lower mini mental status 
examination (MMSE) score, history of neurologic or 
psychiatric disease, and lower preoperative ScO2 were 
independent predictors of postoperative delirium, 
irrespective of hemoglobin or amino-terminal pro B-type 
natriuretic peptide levels, the latter being a marker of 
cardiac insuﬃ  ciency. One important limitation of this 
study is that it did not account for postoperative analgesia 
use, which is a known risk factor for delirium.
Two papers addressed treatment of delirium using 
quetiapine. Th e ﬁ rst is a post hoc analysis of a double 
blind, randomized, placebo controlled study [9,10]. Th e 
authors had already shown that delirium resolves faster 
when quetiapine is added to as-needed haloperidol [9]. In 
the current analysis, they sought to investigate the eﬀ ect 
of quetiapine on individual delirium symptoms of the 
Intensive Care Delirium Screening Checklist (ICDSC). 
Th eir results suggest that quetiapine may lead to a shorter 
time to ﬁ rst resolution of symptom ﬂ uctuation, inatten-
tion, and disorientation, but a longer time to ﬁ rst reso-
lution of agitation and hyperactivity. Th is could be 
relevant when one considers that certain symptoms could 
be disruptive to patient care and maybe even injurious to 
patient and healthcare provider, and hence there is a 
greater urgency to control them.
Th e second article, describing a single institution’s use 
of quetiapine in a small cohort of patients with delirium 
without comparative analysis, reported a reduction in 
need for other antipsychotics once quetiapine was intro-
duced [11]. Adverse events were minor and transient. 
Despite the mixed results from these two studies, overall 
quetiapine has a beneﬁ cial role, at least in alleviating 
certain delirium symptoms and maybe reducing the need 
for other, sometimes less benign anti-psychotics.
Hypothermia
Th erapeutic hypothermia (TH) has become a standard 
practice for out of hospital ventricular ﬁ brillation cardiac 
arrest. TH improves neurological outcome when initiated 
soon, and maintained for 12 to 24 hours after successful 
resuscitation [12,13]. Studies suggest that TH could be 
also beneﬁ cial in other conditions like stroke and 
myocardial infarction [14-16]. Unlike patients who 
survive cardiac arrest and are comatose, however, those 
suﬀ ering a stroke or myocardial infarction are awake and 
therefore could perceive discomfort during cooling. 
Testori and colleagues [17] investigated the feasibility and 
safety of inducing mild hypothermia (32 to 34°C) in 
healthy conscious volunteers using a novel, non-invasive 
surface cooling method. Th is prospective study, which 
was sponsored by the manufacturer of the cooling pads 
(EMCOOLSpad®, Emcools AG, Pfaﬀ staetten, Austria), 
enrolled 16 healthy men aged 18 to 70  years. Th e pads 
were 20 × 30 cm each and consisted of multiple cooling 
cells ﬁ lled with a patented cooling gel. Th ey were applied 
on the back, thorax, abdomen, and thighs and were 
exchanged when thawed. Volunteers were medicated 
with meperidine, buspar to combat shivering. Th e active 
cooling and maintenance period was set at 6  hours, 
during and after which volunteers’ biomarkers (for 
example, esophageal temperature, blood pressure, and so 
on), comfort level, and skin condition were monitored.
Although all individuals achieved temperatures <35°C, 
a target temperature of 32 to 34°C set by the investigators 
was reached in only 6 despite using magnesium sulfate 
infusion in some. Cooling pads had to be exchanged 
often because they were completely thawed before 
reaching temperatures <35°C. Temperature decreased 
from baseline median 36.2°C to 35°C within a median 
time of 53  minutes (median cooling rate of 1.1°C/h). 
Heart and respiratory rates, oxygen saturation and blood 
pressure decreased signiﬁ cantly during cooling, although 
none of the volunteers reported complaints. Further-
more, none felt discomfort that necessitated termination 
of cooling. Mild to moderate skin irritation improved 
over a follow-up period of 7 days. Shivering occurred in 
four volunteers, although increasing the dose of 
meperidine easily controlled it.
In conclusion, healthy, conscious volunteers did not 
describe active cooling using a novel surface method as 
uncomfortable. Th e method was safe, but only partially 
eﬀ ective; an algorithm diﬀ erent from the one used by the 
investigators will be needed to achieve preset 
temperatures.
To address the issue of infections, a widely feared 
complication of TH, Kamps and colleagues [18] studied 
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the eﬀ ect of selective decontamination of the digestive 
tract (SDD) in a group of severely brain-injured patients 
treated with prolonged mild TH on incidence of 
infection. Hypothermia increases the risk of infectious 
complications by interfering with leukocyte function and 
proinﬂ ammatory cytokine release [19,20].
Th is retrospective case-control study compared the 
incidence of infectious complications in adults with 
severe brain injury treated with TH (n = 35) to those not 
treated with TH (n  =  169). Cooling was initiated by 
chilled Ringer’s lactate infusion and maintained for a 
median duration of 107  hours (55 to 168  hours) using 
surface methods. Both groups received SDD, which 
included intravenous cefotaxim and oropharyngeal and 
enteral polymixin, tobramycin, and amphotericin B.
Matching cases and controls using propensity scoring 
that was based on known outcome predictors yielded 2 
relatively homogenous groups of 35 patients each; how-
ever, more patients in the hypothermia group received 
parenteral nutrition (68.6% versus 37.1%; P = 0.013), and 
the maximum dose of midazolam was higher in that 
group too (0.31  ±  0.10  mg/kg/h versus 0.25  ±  0.11  mg/
kg/h; P = 0.043).
Despite a higher rectal (but not oropharyngeal or 
bronchial) bacterial colonization rate in the TH group 
(51.4% versus 25.7%; P = 0.049), these patients were not 
more likely to develop an infectious complication (20% 
versus 34.3%; P = 0.267).
Still the potential biases in this study, which include its 
retrospective, non-randomized and uncontrolled design, 
unbalanced baseline characteristics (for example, paren-
teral nutrition, more severe intracranial hypertension 
necessitating TH, and higher doses of vasoactive drugs), 
and higher mortality in the TH group, favor the 
normothermia group. Th erefore, the results carry some 
relevance by making the case for using SDD in brain-
injured patients at high risk for infectious complications.
Stroke
Despite the availability of acute therapy, ischemic stroke 
remains a major public health issue worldwide. Th is is 
partly because of its high prevalence and morbidity, 
coupled with the still meager use of intravenous throm-
bolysis, continuously fueling interest in neuroprotection 
and other therapies. Tsai and colleagues [21] investigated 
the eﬀ ect of 3-hydroxy 3-methyl-glutaryl coenzyme-A 
(HMG-CoA) reductase inhibitor, or statin, treatment 
before and after stroke on platelet function. Th ey 
measured expression of CD62P and CD63 surface 
molecules [21], which play an important part in platelet 
adhesion and activation during and after stroke [22].
Th e prospective non-randomized and uncontrolled 
cohort study compared blood samples and 90-day out-
comes of 43 patients who were using diﬀ erent forms and 
doses of statins before stroke to those of 129 patients 
without pre-morbid statin use (66 patients administered 
statins within 72  hours of stroke, and 63 patients not 
administered statins). At baseline, patients with pre-
existing statin use were more likely to have diabetes, and 
had signiﬁ cantly lower total and low density lipoprotein 
cholesterol levels than those who were not taking statins. 
In addition, the expression of platelet CD62P and CD63 
molecules were, too, signiﬁ cantly lower. Th e expression 
of CD62P, but not that of CD63, at days 7, 30, and 90 
remained signiﬁ cantly lower in the group with preexisting 
statin use. Initiation of statins after stroke did not have a 
signiﬁ cant eﬀ ect on the expression of these platelet 
surface molecules. In a stepwise logistic regression 
model, severity of stroke, underlying coronary artery 
disease, and pre-existing statin use were independent 
predictors of 90-day outcome; however, the conclusion’s 
validity is questioned by the small sample size and bias 
related to the study design.
In a prospective randomized and placebo-controlled 
trial, Yip and colleagues [23] investigated the safety and 
eﬀ ect of yet another drug, erythropoietin (EPO), on 
outcome and level of circulating endothelial progenitor 
cells (EPCs) following ischemic stroke. Among EPO 
actions is mobilization of EPCs. Th e authors had shown 
in a previous study that an increase in circulating levels 
of EPCs was associated with a favorable outcome in 
patients with ischemic stroke [24].
By comparing patients receiving two doses of 5,000 IU 
each of EPO (n = 83) to those receiving placebo (n = 84) 
and to age and gender-matched healthy volunteers 
(n = 60), the authors reported no adverse events related 
to EPO. Baseline EPC levels were higher in patients 
suﬀ ering an ischemic stroke compared to healthy 
volunteers. In addition, whereas EPC levels early after 
ischemic stroke were comparable between the two study 
groups, that level rose signiﬁ cantly in the active treatment 
group by day  21. Although patients treated with EPO 
were more likely to have less disability from their stroke 
90  days later, this study did not provide longer-term 
follow-up that is more appropriate when considering 
events like recurrent stroke. Furthermore, a relationship 
between EPC levels and recurrent stroke or death 90 days 
after ischemic stroke is unclear.
Intracerebral hemorrhage (ICH) is another, yet 
fortunately less common, type of stroke. It is responsible 
for a disproportionate number of deaths and staggering 
morbidity. Despite interest, enthusiasm and large trials, a 
proven therapy for ICH remains elusive. Early morbidity 
and mortality from ICH is related to structural damage 
caused by the hemorrhage, edema, and inﬂ ammation.
An increase in levels of circulating adhesion molecules 
is thought to contribute to an inﬂ ammatory response in a 
number of diseases aﬀ ecting the central nervous system. 
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Adhesion molecules facilitate movement of activated 
mononuclear cells across endothelial cells of the blood 
brain barrier [25]. In a retrospective study, Wang and 
colleagues [26] revealed that concentrations of soluble 
intercellular cell adhesion molecule-1 (sICAM-1) and 
vascular cell adhesion molecule-1 (sVCAM-1) were 
higher at baseline and increased through day  10 in 
patients with hypertensive ICH. Furthermore, sICAM-1 
was independently associated with outcome. However, 
the latter, deﬁ ned as a modiﬁ ed Rankin scale score of 0 or 
1, was only measured at discharge. Furthermore, the 
patient cohort had relatively small ICH volumes (median 
volume of 10 ml). Th ese limitations might have impacted 
the study results, which do not oﬀ er a clear link between 
levels of adhesion molecules, pathophysiology, and 
ultimate outcome that should be measured at least 
90 days after hemorrhage.
Subarachnoid hemorrhage
Despite its relatively low prevalence, subarachnoid 
hemor rhage (SAH) remains a serious illness with high 
morbidity and mortality. Securing aneurysms, rupture of 
which is to blame for the hemorrhage, has come a long 
way. However, our ability to treat the myriad compli-
cations that accompany SAH, particularly vasospasm 
(VSP) and delayed cerebral ischemia, is still disappointing 
[27]. Hence, it is not surprising to read about many 
publications addressing SAH and the treatment of its 
complications in Critical Care in 2011.
First, a landmark paper published the recommendations 
of a Neurocritical Care Society’s multidisciplinary con-
sen sus conference on the critical care management of 
SAH [28]. Based on the best available evidence, coupled 
with their expert opinion, a group of experienced 
clinicians and researchers addressed issues including 
medical measures to prevent re-bleeding, prophylactic 
use of anticonvulsant drugs, monitoring and managing 
intravascular volume status and cardiopulmonary com-
pli cations, temperature and glucose control and sodium 
homeostasis, current use of statins and magnesium 
sulfate, monitoring and managing delayed cerebral 
ischemia, and ﬁ nally anemia and transfusion, and endo-
crine dysfunction in SAH. Th e purpose of these recom-
mendations is to oﬀ er guidance to clinicians when 
making diagnostic and management decisions in the 
absence of high quality data.
Touching on one of the themes addressed in the 
Neurocritical Care Society’s multidisciplinary consensus 
conference paper, an updated meta-analysis of six 
random ized clinical trials of magnesium sulfate in the 
treatment of VSP was carried out by Wong and colleagues 
[29]. Magnesium is a physiologic antagonist of calcium 
that in in vitro and animal studies causes arterial vaso-
dilation and is neuroprotective [30]. Studies of magnesium 
sulfate in VSP have thus far yielded conﬂ icting and largely 
disappointing results [31-34]. Not surprisingly, and in 
keeping with results of most individual trials, the authors 
found no evidence to lend support for a beneﬁ cial eﬀ ect 
of magnesium sulfate on the incidence of delayed 
ischemic deﬁ cits or overall outcome.
Despite meager scientiﬁ c evidence, emphasis on availa-
bility of natural light in the ICU environment is universal 
[35]. An interesting single center study tested the 
hypothesis that care in an ICU room with a window 
contributes to better outcome in patients with SAH [36]. 
Th is was a retrospective study that mined data on 789 
patients from a large prospective SAH database at 
Columbia University. Care in a room with a window had 
no eﬀ ect on outcome, measured by modiﬁ ed Rankin 
Scale score at discharge, 3  months and 1  year. Further-
more, it had no eﬀ ect on other secondary endpoints like 
length of mechanical ventilation (MV), delirium, ICU 
length of stay, and mortality. Th e results were the same in 
a subgroup analysis that included patients admitted 
during the months of the year with more than 12 hours of 
daylight, and those with better Hunt-Hess grade SAH.
Continuing with outcome studies, a group of investi-
gators assessed the ability of copeptin, the carboxy-
terminal portion of the arginine vasopressin precursor 
peptide, in predicting outcome and incidence of VSP in 
patients with SAH [37]. Recent data found that plasma 
copeptin levels were elevated in patients with traumatic 
brain injury (TBI), ICH and ischemic stroke [38-43].
Th e authors reviewed medical records of 303 patients 
with aneurysmal SAH whose copeptin levels were com-
pared to those of 150 sex- and age-matched healthy 
volunteers. Plasma copeptin levels on admission were 
signiﬁ cantly higher compared to healthy controls 
(21.2 ± 9 pmol/L versus 6.4 ± 1.8 pmol/L; P < 0.001). A 
multivariate analysis identiﬁ ed World Federation of 
Neurological Surgeons (WFNS) score, modiﬁ ed Fisher 
score, and plasma copeptin levels as independent 
predictors of occurrence of VSP, and in-hospital and one-
year mortality. However, copeptin levels did not improve 
the predictive power of either WFNS or the modiﬁ ed 
Fisher score when the variables were combined. 
Conversely, plasma levels of copeptin, along with WFNS 
and modiﬁ ed Fisher score, independently predicted poor 
outcome at one year (deﬁ ned as a Glasgow Outcome 
Scale (GOS) score of 1 to 3), and copeptin signiﬁ cantly 
added to the predictive power of WFNS (P = 0.018) and 
modiﬁ ed Fisher score (P  =  0.029) in this case. Despite 
these encouraging results, using copeptin levels to help 
with prognostication in SAH is not ready for primetime 
yet. Further studies to validate and conﬁ rm these ﬁ ndings 
are needed.
Another paper investigated risk factors for VSP in 
patients with bleeding from arteriovenous malformations 
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[44]. While VSP commonly complicates aneurysmal SAH, 
its incidence, risk factors and consequences in ruptured 
arteriovenous malformation are unknown. A single 
center, retrospective observational study from a busy 
neurosurgical practice in Paris, France found that of 72 
patients with ruptured arteriovenous malformation, 12 
(17%) had VSP deﬁ ned by transcranial Doppler (TCD) 
blood ﬂ ow velocity >120 cm/s in any cerebral artery. Four 
patients underwent digital subtraction angiography with 
results conﬁ rming TCD ﬁ ndings. Furthermore, 6 (8%) of 
the patients with abnormal TCD ﬁ ndings went on to 
develop cerebral infarcts. Multivariate analysis identiﬁ ed 
three risk factors for developing TCD-deﬁ ned VSP: a low 
Glasgow Coma Score (GCS), female gender, and younger 
age. Amount of subarachnoid, intraventricular or 
intraparenchymal blood had no eﬀ ect on risk of VSP, and 
outcome was not aﬀ ected by the development of VSP, 
though the sample size was small and a possible eﬀ ect 
could not be excluded.
Th e need for better tools to monitor critically ill 
patients, mitigate deterioration before or as they occur, 
and predict and improve outcome has led to the 
development of an array of neuromonitoring devices to 
use in the neurointensive care unit. However, and despite 
the enthusiasm those devices have generated, clinicians 
have struggled to meaningfully incorporate them in daily 
practice to ultimately impact outcome. Th is is mainly 
because of a complex link between monitored function 
or marker, intervention and outcome.
A group of researchers studied the utility of combined, 
continuous electroencephalogram (EEG) and somato-
sensory evoked potential (SSEP) recording in 68 critically 
ill patients with SAH (51 patients) and ICH (17 patients) 
[45]. Recordings were carried out for an average of 
10  ±  4  days. As expected, EEG and SSEP changes 
preceded clinical deterioration, intracranial pressure 
(ICP) elevation, and/or new abnormalities on imaging 
studies in the majority of patients. In addition, combined 
EEG and SSEP monitoring increased the odds of predict-
ing deaths when deterioration did occur. SSEP and GCS 
score changes signiﬁ cantly predicted GOS. A caveat to 
these ﬁ ndings is that speciﬁ c interventions to prevent 
and treat deteriorations were not discussed. Continuous 
data monitoring of such tests could prove cumbersome, 
and may be impossible in certain settings and 
institutions.
Meningitis
Bacterial meningitis is associated with many compli-
cations like seizure, hydrocephalus, cerebral venous 
thrombosis, empyema, and stroke. Th ese complications 
add to the already high morbidity of the disease. Diﬀ erent 
mechanisms underlie the development of stroke, the 
most common being arterial narrowing caused by an 
inﬂ ammatory vasculitis. Klein and colleagues [46] 
reviewed medical records of 94 patients with bacterial 
meningitis cared for at one institution looking for the 
incidence of arterial narrowing. Patients underwent TCD 
of commonly insonated cerebral vessels. Although it is 
unclear when and how often TCD was performed, 43% of 
patients had elevated systolic Doppler velocities 
(222  ±  45  cm/s), almost half of whom were diagnosed 
within the ﬁ rst two days. Th e authors found that elevated 
TCD velocities were more often seen in sicker patients 
and those who were treated with corticosteroids, though 
the latter was associated with the former and multivariate 
analysis was not performed. In addition, elevated 
velocities increased the risk of stroke and poor outcome, 
which treatment with nimodipine did not reduce.
Another paper investigated the early diagnosis of 
meningitis [47]. Appropriate therapy of bacterial menin-
gitis relies on early diagnosis. Direct cerebrospinal ﬂ uid 
(CSF) examination only identiﬁ es a bacterial pathogen in 
60 to 80% of cases, and results of cultures are delayed for 
days [48,49]. An earlier study by Viallon and colleagues 
[50] suggested that serum procalcitonin and CSF lactate 
levels could diﬀ erentiate bacterial from viral meningitis 
on presentation in patients who have negative direct CSF 
examination. Th eir current study was aimed at validating 
the value of these markers in accurately making the 
diagnosis of bacterial meningitis upon admission. Th is 
was an observational study comparing patients with 
bacterial (n = 35) to those with viral (n = 218) meningitis 
treated at one hospital over a span of 12  years. Th e 
authors concluded that a CSF lactate level of 3.8 mmol/L 
had a sensitivity of 94% and a speciﬁ city of 97% when 
diﬀ erentiating the two types of meningitis. Similarly, the 
sensitivity and speciﬁ city of a serum procalcitonin of 
0.28 ng/ml was 97% and 100%, respectively. Although the 
number of patients with bacterial meningitis in this study 
is small, the results are nonetheless clinically relevant, 
especially when other parameters like leucocyte count, 
glucose and protein levels, albeit less sensitive, are also 
suggestive of a bacterial etiology. Th us, these ﬁ ndings 
could oﬀ er some hope for an earlier diagnosis, and 
therefore timely appropriate therapy, in those patients 
with unrevealing CSF, or blood, culture results.
Traumatic brain injury
Acute coagulopathy is a dreaded complication of TBI. Its 
prevalence ranges between 10% and 90%, depending on 
how it is deﬁ ned, and is more often encountered in 
severely injured patients. A retrospective review by a 
group of investigators sought to determine the incidence 
of coagulopathy in TBI and understand its relationship 
with outcome [51]. Of 107 patients with isolated TBI, 
65% of whom had severe injury, coagulopathy was 
present on admission in 24%. Another 40% of those 
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without coagulopathy on admission developed abnor-
mali ties in their coagulation parameters within 24 hours 
of admission. Coagulopathy upon admission was asso-
ciated with death (OR 3.75; P = 0.04), though there was 
no interaction between severity of TBI and death that 
one would expect. Finally, because of its retrospective 
nature, information about other consequences and 
treatment of coagulopathy was lacking.
An interesting retrospective review by Roquilly and 
colleagues [52] described the authors’ 9-year experience 
in treating severe TBI-related refractory intracranial 
hypertension in 50 patients with an algorithm-guided 
continuous hypertonic saline infusion. Th e authors used 
an algorithm that considered natriuresis, diuresis and 
patient’s weight, and adjusted the infusion rate of a 20% 
saline solution based on intracranial pressure and the 
diﬀ erence between pre-set and current sodium level. 
Th ough the paper was purely descriptive, the authors 
indicated that the approach was successful in quickly 
lowering ICP, and did not result in major adverse events. 
Validating this algorithm by comparing the approach to 
bolus administration of hypertonic saline should be 
considered the next step, especially in light of the 
controversy regarding the eﬀ ectiveness of mannitol com-
pared to hypertonic saline and its adverse events [53].
Similarly, surgical management of TBI using a bifronto-
temporoparietal decompressive craniectomy was evalu-
ated in a randomized controlled study by Cooper and 
colleagues [54]. Th e long awaited results disappointed 
most who are intimately involved in caring for patients 
with TBI. Th e study recruited adult patients with severe 
non-penetrating TBI with a GCS between 3 and 8 and 
elevated ICP that is refractory to standard therapy. 
Patients were randomized within the ﬁ rst 72 hours after 
TBI to either undergo an extensive decompressive 
craniectomy and durotomy plus standard care (n = 73) or 
standard care alone (n  =  82), while allowing crossover 
from the latter to the former group. Decompressive 
craniectomy decreased ICP, duration of mechanical 
ventilation and ICU length of stay in comparison to 
medical therapy alone, although 6-month outcome 
measured by the extended GOS was worse in the surgical 
group (OR for a worse functional outcome, deﬁ ned as a 
score of 1 to 4 on the extended GOS, was 1.84; 95% CI, 
1.05 to 3.24; P = 0.03). Th is unexpected result could have 
been the product of many variables, as suggested by 
criticism that the study received; these included enrolling 
a small subset of TBI patients with ICP that was not very 
elevated, and possibly suboptimal medical management 
before craniectomy, long accrual time before surgery, the 
operative technique that did not involve division of the 
sagittal sinus and falx cerebri, and possibly worsening 
vasogenic edema following craniectomy and decom-
pression of the brain. In clinical practice, decompressive 
craniectomy in TBI is typically an intervention of last 
resort. Th e results of this study, considering its short-
comings, are unlikely to change the current practice.
Prognostication early in the course of TBI remains a 
vexing and frustrating issue. Th e available tools, including 
clinical examination and brain imaging, are far from 
being perfect and reliable [55]. A multi-center pros-
pective study investigated the value of serum ubiquitin 
C-terminal hydrolase-L1 neuronal protein (UCH-L1), 
and glial ﬁ brillary acidic protein (GFAP) levels in 
predicting outcome in severe TBI [56]. Eighty-one 
patients with severe TBI with or without minor extra-
cranial injury were recruited from four centers. Serial 
(every 6  hours) measurements of both serum UCH-L1 
and GFAP were collected in the ﬁ rst 24  hours and 
compared to those from 167 healthy volunteers. Th e 
authors found signiﬁ cant elevation in levels of both 
biomarkers in their cohort of brain-injured patients. In 
addition, GFAP was higher in patients with focal mass 
lesions, whereas UCH-L1 was higher in patients with 
diﬀ use injury, potentially suggesting diﬀ erent suscepti-
bility of neurons and glia to diﬀ erent patterns of injury. 
Secondary elevations and sustained high levels of either 
biomarker within the ﬁ rst 24  hours were linked to 
secondary insults and surgical intervention. UCH-L1 was 
an independent predictor of mortality at discharge; a 
level of 1.89 ng/ml had a speciﬁ city and sensitivity of 96% 
and 52% in predicting early deaths. Finally, a predictive 
model including age, GCS and UCH-L1 levels accurately 
classiﬁ ed patients as dead versus alive at 6 months 94% of 
the time. Findings of this study are interesting; if validated 
in a larger cohort, a combination of clinical ﬁ ndings, 
brain imaging and biomarkers could aid in early prognos-
tication in patients with TBI.
Peripheral nervous system
A handful of papers published in Critical Care last year 
addressed questions related to the peripheral nervous 
system. Two of these dealt with Guillain-Barre syndrome 
(GBS). Th e ﬁ rst, by El-Bayoumi and colleagues [57], 
described the results of a single center randomized trial 
of intravenous immunoglobulin (IVIg) versus plasma 
exchange (PE) in ventilated children with GBS. In adults, 
treatment with IVIg or PE leads to comparable outcomes 
[58,59], and similar duration of MV [60]. Th e aim of the 
study was to understand the eﬀ ect of the two immuno-
therapies on duration of MV, ICU length of stay and 
overall outcome in children. With a small sample size 
(IVIg 20 patients; PE 21 patients), the investigators found 
that outcome, measured by the ability to ambulate 
independently 4  weeks after discharge from ICU, was 
similar in the 2 groups; yet children treated with PE had a 
signiﬁ cantly shorter duration of MV compared to those 
treated with IVIg (11  ±  1.5  days versus 13  ±  2.1  days; 
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P  =  0.037). Conﬁ rmation of these ﬁ ndings by larger 
randomized trials could have an important impact on 
how we treat children with severe GBS.
Th e second study sought to answer an important 
question that clinicians caring for patients with GBS are 
faced with: how to decide early in the course of the illness 
who will need a tracheostomy. Fourrier and colleagues 
[61] reviewed medical records of 61 adult patients with 
GBS treated at their institution between 1996 and 2009. 
Of those, 40 patients required MV, 12 for equal or less 
than, and 28 for more than 15  days. Th ree of the 12 
patients in the shorter MV group and 25 of the 28 
patients in the longer MV group underwent tracheo-
stomy. Th e authors found that the combination of a 
sciatic nerve conduction block on electromyography and 
lack of foot ﬂ exion after completion of immunotherapy 
was an excellent predictor of prolonged MV (100% 
speciﬁ city). Th is ﬁ nding awaits validation before being 
used to predict prolonged MV and hence the need for 
tracheostomy in this patient population.
Critical illness polyneuropathy and myopathy (CIPNM) 
is another cause of ﬂ accid paralysis in the ICU, though 
unlike GBS, which is the reason for admission, CIPNM 
develops during a long ICU stay. Th e exact patho physio-
logy of CIPNM is yet to be elucidated, although risk 
factors like use of neuromuscular blocking agents, 
amino glycosides, and high dose corticosteroids have 
been incriminated [62,63]. More recently, calcium 
homeo stasis disturbances in critically ill, septic patients 
have been suggested to play a role in the pathogenesis of 
CIPNM [64].
Anastasopoulos and colleagues [65] prospectively 
followed 190 consecutive critically ill patients with ICU 
length of stay longer than 7 days who were admitted to 
their institution over a 9-month period. Forty of the 190 
patients developed CIPNM, which was conﬁ rmed by 
electromyography. Patients with CIPNM had a longer 
duration of MV (32.88 ± 22.2 days versus 14.4 ± 9 days; 
P  <  0.05) than those without CIPNM. Episodes of pro-
longed hypocalcemia were common, especially among 
patients with septic shock. Logistic regression analysis 
showed that hypocalcemia, hypercalcemia and septic 
shock were independently associated with the develop-
ment of CIPNM. Th e severity of hypocalcemia, however, 
did not correlate with that of CIPNM. Th e proposed 
mechanism by which hypocalcemia could lead to CIPNM 
involves elevated intracellular calcium concentration 
interfering with proteolysis of myosin thick ﬁ lament. 
Finally, whether hypocalcemia is a cause or byproduct of 
severe illness during which CIPNM is more likely to 
occur remains unclear, and more studies are needed to 
prove a cause-eﬀ ect relationship.
To evaluate weakness in critically ill patients, clinicians 
and researchers use the Medical Research Council 
(MRC) sum score, which is the average MRC strength 
score combined for 12 speciﬁ ed muscle groups [66]. Th e 
feasibility and reliability of this score was tested in 
patients with GBS, and in outpatient survivors of critical 
illness. A recent study suggested that performing manual 
strength testing for the MRC sum score is not feasible in 
a large number of patients in the ICU [67]. Th is is most 
often related to impaired attention and comprehension. 
In addition, albeit the sample size was small (n = 30) and 
patients developing weakness were few, the interobserver 
agreement for individual muscle group and the total 
MRC sum score was poor, especially when patients were 
uncooperative. Th is study raises an important issue, 
given that the MRC sum score is widely used and 
reported in investigations of weakness in the ICU. Th is 
leaves room for speculation about the validity of results 
of such studies.
Conclusion
Th e unrelenting interest in neuroscience research was 
the impetus behind many good quality investigations 
published in Critical Care in 2011. Th ese expanded our 
knowledge about delirium, its risk factors and diﬀ erent 
pathophysiologic mechanisms, therapy for vasospasm, 
and stroke, complications of TBI, diagnosis of meningitis, 
and respiratory failure in GBS. Some of these articles 
could be the precursor to larger trials that advance our 
knowledge of diseases, their treatment and outcome in 
the neurointensive care unit.
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